You may hear about two radiation treatments for bone metastases: external-beam radiotherapy (EBRT) and Lu-177 PSMA therapy. Both use radiation, but they work differently. Which one is right for you - or whether you need both - depends on your situation.
This article focuses on men with PSMA-positive mCRPC and bone metastases. It compares EBRT and Lu-177 PSMA therapy side by side so you can have a clearer conversation with your oncology team.
The short answer: EBRT targets one or a few painful spots from outside the body. Lu-177 PSMA therapy is a systemic treatment that travels through the bloodstream and finds prostate cancer cells wherever they are. The two treatments are not competing options in most cases. They often play different roles in the same overall plan.
How do Lu-177 PSMA therapy and external-beam radiotherapy compare for bone metastases in mCRPC?
| Factor | Lu-177 PSMA Therapy | External-Beam Radiotherapy (EBRT) |
|---|---|---|
| Treatment reach | Systemic - travels through the bloodstream to reach cancer cells throughout the body | Local and focal - targets one or a few specific bone lesions from outside the body |
| Primary goal | Slow overall disease progression and extend survival | Relieve pain at a specific site; reduce risk of fracture or spinal cord compression |
| Key eligibility gate | PSMA-positive result on a PSMA-PET/CT scan; prior androgen receptor pathway inhibitor (ARPI) therapy required | Painful or structurally at-risk bone lesion confirmed on imaging; no PSMA-PET scan required |
| Number of sessions | Up to 6 infusion cycles, spaced approximately 6 weeks apart | 1 to 10 sessions, depending on the fractionation schedule your team chooses |
| Common side effects | Fatigue, dry mouth, nausea, reduced blood cell counts | Skin reaction at the treated site, local fatigue, temporary pain flare after treatment |
| Key evidence | VISION trial: median overall survival 15.3 months vs 11.3 months with standard care alone, hazard ratio 0.62 (P less than 0.001) | Research suggests approximately 60-70% of patients experience some pain relief; around 25% achieve complete relief |
Sources: Sartor et al., New England Journal of Medicine 2021 (VISION trial); PMC - The role of radiation therapy in metastatic castration-resistant prostate cancer.
The key difference: Lu-177 PSMA therapy aims to control the whole disease, while EBRT addresses a specific problem in one place. These roles are not mutually exclusive. Some patients use a short course of EBRT for an urgent painful spot and then receive Lu-177 PSMA cycles to treat the broader disease. Your team's job is to work out the right order and combination for your situation.
What is external-beam radiotherapy, and what does it do for bone metastases?
External-beam radiotherapy uses a machine that aims a focused beam of high-energy radiation at a specific area from outside the skin. The beam is shaped to concentrate radiation on a bone lesion while protecting nearby tissue.
For bone metastases in prostate cancer, EBRT is used for two main reasons. First, it can reduce or stop bone pain when a specific lesion is causing discomfort. Second, it can lower the risk of a fracture or nerve compression when a lesion sits in a weight-bearing bone or close to the spinal cord.
The treatment is given in one to ten sessions. A single high dose of 8 Gray (Gy) gives similar pain relief to 30 Gy spread over 10 sessions for many patients, though you may need another treatment more often with the single-dose approach. Your radiation oncologist will choose the schedule based on where the lesion is, how large it is, and your overall condition. A published review comparing fractionation schedules for bone metastases in prostate cancer found both approaches to be clinically reasonable depending on the setting.
The main limitation of EBRT is that it only treats the spot you aim at. If bone metastases have spread to many sites, EBRT can address one or two of them, but it will not reach the rest. That is why EBRT alone is rarely the full answer when cancer has spread widely through the skeleton.
If you have bone lesions near the spine and are wondering whether Lu-177 PSMA therapy is safe in that setting, see our article on spine bone metastases and Lu-177 PSMA safety, which covers what the evidence says about lesion location and radiation toxicity.
How does Lu-177 PSMA therapy treat bone metastases?
Lutetium Lu-177 vipivotide tetraxetan (brand name Pluvicto) is a radioligand therapy. It has two parts: a molecule that targets and binds to PSMA (prostate-specific membrane antigen) on prostate cancer cells, and a radioactive payload - lutetium-177 - that delivers a targeted radiation dose directly to those cells.
After it is infused into a vein, the drug circulates through the bloodstream and attaches to PSMA-expressing prostate cancer cells wherever they are - in bone, lymph nodes, or other tissue. Radiation comes from inside the cancer cell, not from an external machine. This is what makes it systemic: it can reach cancer cells in multiple bone lesions at the same time, not just one spot.
The phase 3 VISION trial enrolled 831 patients with mCRPC and found that adding lutetium Lu-177 vipivotide tetraxetan to standard care extended median overall survival to 15.3 months versus 11.3 months for standard care alone. That is a hazard ratio of 0.62, meaning men in the treated group had about a 38% lower risk of death during the study period. Imaging-based progression-free survival also improved markedly: 8.7 months versus 3.4 months. These results were published in the New England Journal of Medicine in 2021.
The US Food and Drug Administration approved Pluvicto for PSMA-positive mCRPC, with the indication expanded in 2025 to include patients for whom it is appropriate to delay taxane-based chemotherapy. The Prostate Cancer Foundation explains what this expanded approval means for patients in practical terms.
Because Lu-177 PSMA therapy works throughout the body, it may reduce the burden of multiple bone lesions at the same time - something EBRT is not designed to do.
Who qualifies for each treatment?
The two treatments have very different eligibility requirements, and this often determines which one is realistic for you at a particular time.
For EBRT, the eligibility bar is lower. You need a bone lesion confirmed on imaging - a CT scan, bone scan, or MRI - and a clinical assessment that the lesion is causing pain or poses a structural risk. You don't need a PSMA-PET scan. Most patients with bone metastases, even those who don't qualify for intensive systemic therapy, can get EBRT for a specific painful spot.
For Lu-177 PSMA therapy, several criteria must be met. Your tumor must have enough PSMA expression on a PSMA-PET/CT scan, because lesions that don't show up on the scan are unlikely to respond to the drug. Your disease must be classified as mCRPC, meaning it has continued to grow despite castration therapy. You must have received prior ARPI therapy. You also need adequate kidney function, liver function, and blood counts. If you are unsure what your PSMA-PET results mean for your eligibility, our article on PSA doubling time and Lu-177 PSMA eligibility explains how disease pace affects treatment timing.
Not every man with bone metastases will qualify for Lu-177 PSMA therapy. And even among those who do qualify, access varies widely by country. If your oncologist has not raised it as an option, or if it is not available where you live, you may want to request a Lu-177 eligibility review through Art of Healing Cancer, where nuclear medicine teams can review your scan results and disease history to assess whether you are a candidate.
Can you use Lu-177 PSMA therapy and EBRT together or in sequence?
Yes. In many cases, you can use both treatments or use them one after the other, as long as your specialists coordinate the plan carefully.
A common scenario: you have widespread bone metastases and qualify for Lu-177 PSMA therapy, but one specific lesion is causing severe pain or sits close to the spinal cord. In that situation, your team might recommend a short course of EBRT to that site first to handle the urgent problem, and then proceed with Lu-177 PSMA cycles to treat the broader disease. The two treatments tackle different problems at different scales.
The timing must be coordinated with care. Both treatments can affect how bone marrow produces blood cells. Your radiation oncologist and nuclear medicine team may need to wait between treatments to let your bone marrow recover before starting the next phase. This coordination is routine at centers that specialize in theranostics, but it requires direct communication between both specialists.
Having had EBRT at some bone sites doesn't automatically disqualify you from Lu-177 PSMA therapy later. What matters is your current bone marrow health and the total radiation dose your bone marrow has already received. Your team will reassess your eligibility based on your blood counts, kidney function, and disease picture at the time of evaluation. For more on how to monitor bone health during systemic therapy, see our article on bone density and fracture risk during Lu-177 PSMA therapy.
Questions to bring to your oncology team
If you are trying to work out whether EBRT, Lu-177 PSMA therapy, or both are options for you, these questions can help focus the conversation with your team:
- Have I had a PSMA-PET/CT scan, and what did it show about PSMA expression across my bone lesions?
- Are any of my bone lesions causing a structural risk - fracture risk or spinal cord compression - that needs urgent attention?
- How many bone lesions do I have? Are they in one or two places, or spread throughout my skeleton?
- Have I already received the prior therapies (ARPI therapy, and taxane chemotherapy if required) needed to qualify for Lu-177 PSMA?
- What are my current kidney function, hemoglobin, and platelet levels? These affect eligibility for systemic therapy.
- If I receive EBRT now, would that affect my eligibility for Lu-177 PSMA therapy later?
- Is Lu-177 PSMA therapy available to me locally, or would I need to travel to access it?
These questions help your team understand whether you are dealing with a focal problem that EBRT can handle, widespread disease that needs a system-wide treatment, or a situation where both are needed in sequence. The answers change what your plan looks like going forward.
If you would like an independent review of your PSMA-PET scan results and medical records to clarify whether you qualify for Lu-177 PSMA therapy, you can send your records through the Lutetium Therapy contact form. If Lu-177 PSMA is not the right fit at this time, a second opinion on alternative approaches is also available.
When to talk to your doctor
Speak with your oncologist or nuclear medicine team promptly if your pain is harder to control, if your cancer has spread to multiple bone sites, if you have not yet had a PSMA-PET scan, or if your team hasn't discussed Lu-177 PSMA therapy as a possible option. If you are considering traveling internationally for treatment, confirm your eligibility before making any travel plans.
This article is for general information and is not a substitute for medical advice. Always consult your oncologist or care team about your specific situation.
Frequently asked questions
What is the main difference between Lu-177 PSMA therapy and external-beam radiotherapy for bone metastases?
EBRT is a local treatment that aims radiation from a machine outside the body at one or a few specific bone lesions, mainly to relieve pain or reduce fracture risk. Lu-177 PSMA therapy is a systemic treatment that circulates through the bloodstream and targets PSMA-expressing prostate cancer cells throughout the body. EBRT treats only the specific spot that is targeted; Lu-177 PSMA may reach cancer cells in multiple bone lesions at the same time.
Do I need a PSMA-PET scan before I can get external-beam radiotherapy for a painful bone metastasis?
No. EBRT does not require a PSMA-PET scan. Your team can plan EBRT based on conventional imaging such as a bone scan, CT, or MRI. A PSMA-PET scan is required to confirm eligibility for Lu-177 PSMA therapy, not for EBRT. This means EBRT is often more immediately accessible, even before full PSMA eligibility testing has been completed.
Can I have EBRT and Lu-177 PSMA therapy at the same time, or do I have to choose one?
In many cases both can be used, but timing needs careful coordination between your radiation oncologist and nuclear medicine team. A common approach is to use EBRT first to address an urgent painful or dangerous bone lesion, and then proceed with Lu-177 PSMA cycles to treat the broader disease. Both treatments can affect bone marrow, so your team will plan around your blood counts and overall reserves before starting each phase.
Will having EBRT now rule me out for Lu-177 PSMA therapy later?
Not automatically. Prior EBRT does not disqualify you from Lu-177 PSMA therapy on its own. What matters is your current bone marrow reserve and the total radiation dose your marrow has received over time. Your eligibility for Lu-177 PSMA will be assessed based on your blood counts, kidney function, and current disease picture at the time you are evaluated.
How long does pain relief from EBRT for bone metastases usually last?
Pain relief from EBRT may begin within days to a few weeks of treatment and can last for months. Research suggests approximately 60-70% of patients experience some degree of pain reduction, and around 25% achieve complete pain relief. Keep in mind that EBRT treats only the specific site that was irradiated - cancer activity in other bone sites can still cause pain and may need separate treatment.
What if my PSMA-PET scan shows that not all of my bone lesions are PSMA-positive?
This is called heterogeneous PSMA expression and is an important factor in treatment planning. Lesions that do not appear on the PSMA-PET scan will not be targeted by Lu-177 PSMA therapy. Your team may consider EBRT for PSMA-negative lesions that are causing pain or structural risk, while using Lu-177 PSMA therapy for the PSMA-positive disease burden elsewhere. A specialist in theranostics can review your scan and recommend the best combined approach.